French software developer Dassault Systemes is reportedly in negotiations to acquire ArisGlobal, a company that makes software used in drug trials, from investment firm Nordic Capital in a deal valued at roughly $2 billion, according to a report published Thursday by the Financial Times. The newspaper cited individuals familiar with the situation.
If completed, the acquisition would mark a significant expansion of Dassault Systemes’ presence in the life sciences software sector. It would also stand as the company’s second-largest purchase ever, trailing only its $5.8 billion acquisition of clinical trial software company Medidata Solutions back in 2019.
However, the Financial Times cautioned that a final agreement is far from guaranteed, and the negotiations could collapse before any deal is reached.
Reuters, which first distributed the report, noted it was unable to independently confirm the details at the time of publication.
Earlier this year in April, Dassault Systemes disclosed first-quarter revenue of 1.51 billion euros, equivalent to approximately $1.77 billion, a figure that matched analyst expectations.
The company, which develops software for automakers, aircraft manufacturers, and industrial businesses, has faced headwinds from a prolonged downturn in the global automotive industry. In response, Dassault Systemes has been shifting its focus toward artificial intelligence and data center technologies as new avenues for growth.
Representatives for Dassault Systemes, ArisGlobal, and Nordic Capital were not immediately available to respond to requests for comment.
